Alphabet's GV Leads Funding in Gene Editing Company Verve Therapeutics

GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

Comments

Popular posts from this blog

India’s Upcoming Digital Personal Data Protection Bill: Ten Things to Know About the Proposed Legislation